Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 9/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29961030 | 1.00 | AHR (0.50) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL10061744 | 0.75 | NPC1 (0.46) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL11710281 | 0.75 | NPC1 (0.50) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL4811332 | 0.75 | ALDH1A1 (0.60) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL1762488 | 0.73 | AHR (0.59) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL9373684 | 0.73 | CA9 (0.54) | AHRLMNAL3MBTL1ATMMAPT | |
| SCHEMBL6606073 | 0.70 | PDE3B (0.56) | NPC1RAB9ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL20596892 | 0.69 | L3MBTL1 (0.38) | SMN1; SMN2LMNAL3MBTL1ATMMAPT | |
| SCHEMBL27076402 | 0.69 | HTR5A (0.44) | AHRL3MBTL1ATMMAPTACHE | |
| SCHEMBL21312022 | 0.68 | NPC1 (0.41) | AHRPDK2NPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0510235-A1 | Novel benzoxazine or benzothiazine derivatives and process for the preparation of the same | DONG-A PHARM. CO., LTD. (KR) | 1992-10-28 | — | — | EP | claimed |
| JP-63170385-A | — | — | None | — | — | JP | disclosed |
| US-20240208953-A1 | \"Cyclopenta[c]pyrrol Negative Allosteric Modulators of NR2B\ | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-06-27 | — | — | US | disclosed |
| EP-4313041-A1 | NOVEL CYCLOPENTAL[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157072-A | Novel cyclopento [ c ] pyrrole NR2B negative allosteric modulators | 诺华股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2022204336-A1 | NOVEL CYCLOPENTAL[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | NOVARTIS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2010-04-29 | — | — | US | disclosed |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
| US-7351825-B2 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-7351825-B2 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2008-04-01 | — | — | US | disclosed |
| JP-S63170385-A | BENZOTHIAZINE DERIVATIVE AND AGRICULTURAL AND HORTICULTURAL GERMICIDE | KUMIAI CHEM IND CO LTD | 1988-07-14 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | MMP13, MMP11, MMP3 | AHR 288/4885PDK2 3082/4885NPC1 1780/4885 |
| US-20240208953-A1 | \"Cyclopenta[c]pyrrol Negative Allosteric Modulators of NR2B\ | GRIN2C, GRIN2B, GRIN2A | AHR 2327/4885PDK2 2851/4885NPC1 2885/4885 |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MMP13, MMP9, MMP11 | AHR 528/4885PDK2 2671/4885NPC1 2112/4885 |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | AHR 528/4885PDK2 2671/4885NPC1 2112/4885 |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | AHR 566/4885PDK2 2706/4885NPC1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.